DRMA
Dermata Therapeutics, Inc.
Healthcare — Biotechnology
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
None
1 analysts
$1.10
(0.00%)
Target:
$4.00
(263.6%)
Price History
52-Week Range
Sign in to add DRMA to a watchlist or set price alerts.
Fundamentals
| Market Cap | $5.55M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.36 |
| EPS (TTM) | $-4.17 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -103.58% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $4.00 |
| Analysts | 1 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 62.7 |
| Beta | 0.69 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $8.00 |
| 52-Week Low | $1.10 |
| 50-Day Avg | $1.26 |
| 200-Day Avg | $2.27 |
| Avg Volume | 73.4K |
| Volume | 178.1K |
Performance Analysis
BULLISHDRMA shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($1.10), which could present a value opportunity.
+
RSI at 62.7 shows positive momentum.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none" from 1 analysts.
+
Average analyst target of $4.00 implies 263.6% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:06 UTC
Back to Screener Export Report